Roche, Blueprint raise pressure on Lilly with new Gavreto approvalThe FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting Share XRoche, Blueprint raise pressure on Lilly with new Gavreto approvalhttps://pharmaphorum.com/news/roche-blueprint-raise-pressure-on-lilly-with-new-gavreto-approval/
Blueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drugCancer drugs firm Blueprint Medicines has gained a second US approval, with its Gavreto (pralsetinib) daily pill that Share XBlueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drughttps://pharmaphorum.com/news/blueprint-and-roche-take-on-lilly-as-fda-approves-ret-targeting-lung-cancer-drug/
European regulators back Blueprint’s Ayvakyt for stomach tumoursEuropean regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain Share XEuropean regulators back Blueprint’s Ayvakyt for stomach tumourshttps://pharmaphorum.com/news/european-regulators-back-blueprints-ayvakyt-for-stomach-tumours/
Roche signs $1.7bn deal with Blueprint around cancer drug pralsetinibRoche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that Share XRoche signs $1.7bn deal with Blueprint around cancer drug pralsetinibhttps://pharmaphorum.com/news/roche-signs-1-7bn-deal-with-blueprint-around-cancer-drug-pralsetinib/
Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug The FDA has turned down Blueprint Medicines’ Ayvakit for more general use in gastrointestinal stromal tumour – Share XBlueprint pays the price of Ayvakit phase 3 miss as FDA rejects drughttps://pharmaphorum.com/news/blueprint-pays-the-price-of-ayvakits-phase-3-miss-as-fda-rejects-drug/
FDA clears Lilly’s Retevmo for RET-positive lung, thyroid cancersEli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting Share XFDA clears Lilly’s Retevmo for RET-positive lung, thyroid cancershttps://pharmaphorum.com/news/fda-clears-lillys-retevmo-for-ret-positive-lung-thyroid-cancers/
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinibEli Lilly says it is eyeing an FDA verdict for RET-positive tumour treatment selpercatinib in the third quarter Share XLilly keeps ahead of Blueprint with swift FDA review for selpercatinibhttps://pharmaphorum.com/news/lilly-keeps-ahead-of-blueprint-with-swift-fda-review-for-selpercatinib/
Ipsen adds Blueprint’s FOP rare disease drug to pipeline for $535mIpsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a Share XIpsen adds Blueprint’s FOP rare disease drug to pipeline for $535mhttps://pharmaphorum.com/news/ipsen-adds-blueprints-fop-rare-disease-drug-to-pipeline-for-535m/
